Home > News > BioSante Pharmaceuticals Initiates Phase III Study of LibiGel®
December 28th, 2006
BioSante Pharmaceuticals Initiates Phase III Study of LibiGel®
Abstract:
BioSante Pharmaceuticals, Inc. (Amex: BPA) announced today that it has initiated a Phase III safety and efficacy trial of LibiGel® (transdermal testosterone gel) in the treatment of female sexual dysfunction (FSD). The double-blind, placebo-controlled Phase III trial will enroll approximately 360 surgically menopausal women for a six-month clinical trial, conducted under a Phase III protocol and investigational new drug application (IND) reviewed by and on file with the U.S. Food and Drug Administration (FDA).
Source:
businesswire.com
Related News Press |
Announcements
Diamond glitter: A play of colors with artificial DNA crystals May 17th, 2024
Finding quantum order in chaos May 17th, 2024
Oscillating paramagnetic Meissner effect and Berezinskii-Kosterlitz-Thouless transition in cuprate superconductor May 17th, 2024
Human Interest/Art
Drawing data in nanometer scale September 30th, 2022
Scientists prepare for the world’s smallest race: Nanocar Race II March 18th, 2022
Graphene nanotubes revolutionize touch screen use for prosthetic hands August 3rd, 2021
JEOL Announces 2020 Microscopy Image Grand Prize Winners January 7th, 2021
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||